AD

Adjuvant Capital — Seed & Pre-Seed VC Firm ($250K–$2.5M Checks)

VC
New York, NYProfile updated November 2026Website

Adjuvant Capital is a Seed, Pre-Seed venture capital firm based in New York, NY investing in Healthcare. The firm typically writes $250K–$2.5M checks and has 20 portfolio companies in our records.

Check size
$250K–$2.5M
Portfolio
20 companies on record
Partners
5 listed
AUM
$300M
Stage
Seed, Pre-Seed
Sectors
Healthcare
HQ
New York, NY

Last verified: 2026-05-21

How to approach: warm intro preferred
Stage

Seed, Pre-Seed

Check Size

$250K – $2.5M

AUM

$300M

Portfolio

20+ companies

Team

5 partners

About Adjuvant Capital

Adjuvant Capital is a venture capital firm headquartered in New York, NY. The firm invests in innovative technologies and therapies addressing major global health challenges, including oncology and genetic therapies.

Adjuvant Capital focuses on the healthcare, vaccines, and oncology sectors. It typically participates in seed, pre-seed, and early-stage financings with check sizes ranging from $250K to $2.5M. The firm has $300M in assets under management and prefers to be approached via warm introduction.

Investment Thesis

Invests in innovative technologies and therapies for major global health challenges, including oncology and genetic therapies.

How Adjuvant Capital invests

Adjuvant Capital is a vc firm based in New York, NY. The firm invests at the Seed, Pre-Seed stages, with a focus on Healthcare.

Adjuvant Capital typically writes checks of $250K–$2.5M per investment, backed by approximately $300M in assets under management.

Investing since at least 2019, Adjuvant Capital has backed 20 companies in our records, including LimmaTech Biologics, Curevo Vaccine, Memo Therapeutics.

Partners & Team

KA

Kabeer Aziz

Partner

global health technology commercialization
emerging markets
public health innovation
GR

Glenn Rockman

Managing Partner

infectious diseases
maternal & child health
neglected tropical diseases
global health technologies
PD

Philippe Dro

Partner

biopharma
medical devices
vaccine development
European investments in health technologies
GC

Gerard Cunningham

Operating Partner

operational execution
scale-up of global health technologies
manufacturing / supply chain
public health delivery
KA

Kate Antrobus

Venture Partner

industrialization models
portfolio strategy
access in sub-Saharan Africa
blended finance in global health

Industry Focus

Invests In

Healthcare

Recent Activity

Investment Track Record

Adjuvant Capital has recorded investments in 21 companies. Its earliest recorded investment was made in 2019 and its most recent in 2023.

The firm's portfolio includes LimmaTech Biologics (2023, vaccine), Curevo Vaccine (2022, vaccine), Memo Therapeutics (2022, therapeutic), Antiva Biosciences (2021, therapeutic), Excision BioTherapeutics (2021, therapeutic), Pulmocide (2021, inhaled therapeutic), 54gene (2020, platform), ChromaCode (2020, platform), Codagenix (2020, platform), Evofem (2020, contraceptive), Frontier Nutrition (2020, lipid-based nutritional supplements), LakeShore Biopharma (2020, vaccine), MinervaX (2020, vaccine), Univercells (2020, process innovation), and VitriVax (2020, vaccine).

Portfolio Companies (20)

2023

LI

LimmaTech Biologics

Vaccine

Vaccine development company working to halt AMR and STI infections.

2022

CU

Curevo Vaccine

Vaccine

Next-generation subunit vaccines, initially targeting varicella and shingles.

ME

Memo Therapeutics

Therapeutic

Antibody discovery platform, initially targeting Nipah virus, SARS-CoV-2, CMV and BKV.

2021

AN

Antiva Biosciences

Therapeutic

Novel non-surgical therapeutic candidate to treat pre-cancerous cervical lesions caused by HPV.

PU

Pulmocide

Inhaled Therapeutic

Novel therapies for patients suffering from serious acute and chronic respiratory diseases.

EX

Excision BioTherapeutics

Therapeutic

CRISPR-based therapies for chronic viral infectious diseases such as HIV and hepatitis B.

2020

LA

LakeShore Biopharma

Vaccine

LakeShore is scaling up undersupplied global health vaccines and developing new biologics.

CH

ChromaCode

Platform

ChromaCode's HD-PCR technology enhances multiplexing capabilities on existing hardware.

CO

Codagenix

Platform

Codagenix uses emerging computational and synthetic biology tools to rationally design vaccines.

54

54gene

Platform

54gene is using African genetic data to drive discoveries in drug and vaccine development.

How to pitch Adjuvant Capital
  • •Raising at Seed, Pre-Seed? You're squarely in their sweet spot.
  • •Lead with your fit in Healthcare — the sectors they actively back.
  • •Size your ask to their typical $250K – $2.5M check.
  • •warm intro preferred
  • •Address your outreach to a specific partner, such as Kabeer Aziz, Partner.
  • •A warm introduction beats a cold email. Get matched and request an intro.

Featured In

Browse More Investors

Fundraising resources

Frequently Asked Questions

See if Adjuvant Capital is a match for your startup

Upload your pitch deck to see how well you match with Adjuvant Capital and 10,000+ other investors.

Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT

Is this your profile? Request a correction or removal